Drug interactions
Cytarabine + Idecabtagene vicleucel
Severity: Major
Cytarabine and Idecabtagene vicleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Cytarabine causes profound myelosuppression and immunosuppression, which can add to the cytopenias and infection risk after CAR-T therapy. Chemotherapy near the time of infusion may also compromise CAR-T expansion and persistence.
What this interaction means in plain words
Cytarabine and Idecabtagene vicleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Cytarabine belongs to Oncology; Idecabtagene vicleucel belongs to Oncology.
Why it happens
Additive myelosuppressive and immunosuppressive effects, with possible cytotoxic effects on infused T cells.
What to do
Avoid cytarabine around infusion and during the early recovery period unless clearly needed. If given, monitor blood counts and infections closely and use prophylaxis per protocol.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Cytarabine and Idecabtagene vicleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Cytarabine
Other interactions of Idecabtagene vicleucel
Frequently asked questions
Can I take Cytarabine with Idecabtagene vicleucel?
MediHelp rates the interaction as major. Cytarabine and Idecabtagene vicleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Cytarabine causes profound myelosuppression and immunosuppression, which can add to the cytopenias and infection risk after CAR-T therapy. Chemotherapy near the time of infusion may also compromise CAR-T expansion and persistence.
How serious is the interaction between Cytarabine and Idecabtagene vicleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid cytarabine around infusion and during the early recovery period unless clearly needed. If given, monitor blood counts and infections closely and use prophylaxis per protocol.
What other medicines interact with Cytarabine?
MediHelp also lists interactions of Cytarabine with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Belatacept. The full list is on the Cytarabine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
